JP2006316058A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006316058A5 JP2006316058A5 JP2006132110A JP2006132110A JP2006316058A5 JP 2006316058 A5 JP2006316058 A5 JP 2006316058A5 JP 2006132110 A JP2006132110 A JP 2006132110A JP 2006132110 A JP2006132110 A JP 2006132110A JP 2006316058 A5 JP2006316058 A5 JP 2006316058A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxyethyl
- ethyl
- pyrazolo
- methylamino
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2-Ethoxyethyl Chemical group 0.000 claims 103
- 239000013078 crystal Substances 0.000 claims 36
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 36
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims 9
- 238000001237 Raman spectrum Methods 0.000 claims 9
- 238000010521 absorption reaction Methods 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims 9
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- ZUHZNKJIJDAJFD-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCC)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)CC)=NC=1NC1=CC(C)=CC=N1 ZUHZNKJIJDAJFD-UHFFFAOYSA-N 0.000 claims 4
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68044505P | 2005-05-12 | 2005-05-12 | |
| US68171105P | 2005-05-17 | 2005-05-17 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009001627A Division JP4996631B2 (ja) | 2005-05-12 | 2009-01-07 | 無水結晶形態のＮ−［１−（２−エトキシエチル）−５−（Ｎ−エチル−Ｎ−メチルアミノ）−７−（４−メチルピリジン−２−イル−アミノ）−１Ｈ−ピラゾロ［４，３−ｄ］ピリミジン−３−カルボニル］メタンスルホンアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006316058A JP2006316058A (ja) | 2006-11-24 |
| JP2006316058A5 true JP2006316058A5 (cg-RX-API-DMAC7.html) | 2008-12-11 |
| JP4271695B2 JP4271695B2 (ja) | 2009-06-03 |
Family
ID=37106941
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006132110A Expired - Fee Related JP4271695B2 (ja) | 2005-05-12 | 2006-05-11 | 無水結晶形態のＮ−［１−（２−エトキシエチル）−５−（Ｎ−エチル−Ｎ−メチルアミノ）−７−（４−メチルピリジン−２−イル−アミノ）−１Ｈ−ピラゾロ［４，３−ｄ］ピリミジン−３−カルボニル］メタンスルホンアミド |
| JP2009001627A Expired - Fee Related JP4996631B2 (ja) | 2005-05-12 | 2009-01-07 | 無水結晶形態のＮ−［１−（２−エトキシエチル）−５−（Ｎ−エチル−Ｎ−メチルアミノ）−７−（４−メチルピリジン−２−イル−アミノ）−１Ｈ−ピラゾロ［４，３−ｄ］ピリミジン−３−カルボニル］メタンスルホンアミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009001627A Expired - Fee Related JP4996631B2 (ja) | 2005-05-12 | 2009-01-07 | 無水結晶形態のＮ−［１−（２−エトキシエチル）−５−（Ｎ−エチル−Ｎ−メチルアミノ）−７−（４−メチルピリジン−２−イル−アミノ）−１Ｈ−ピラゾロ［４，３−ｄ］ピリミジン−３−カルボニル］メタンスルホンアミド |
Country Status (23)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7676953B2 (en) | 2006-12-29 | 2010-03-16 | Signature Control Systems, Inc. | Calibration and metering methods for wood kiln moisture measurement |
| WO2009050554A2 (en) * | 2007-10-19 | 2009-04-23 | Pfizer Inc. | Treatment of central nervous system disorders |
| US20130274235A1 (en) * | 2010-10-08 | 2013-10-17 | The General Hospital Corporation | Treatment of motor neuron disease |
| WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| AU2012244550C1 (en) | 2011-04-21 | 2017-06-22 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| CN102952138B (zh) * | 2011-08-17 | 2016-07-06 | 上海特化医药科技有限公司 | 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用 |
| WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2014060112A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| CA2888160A1 (en) | 2012-10-23 | 2014-05-01 | Pfizer Inc. | Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy |
| CA2893256A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| WO2014125394A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| MD20150071A2 (ro) | 2013-02-19 | 2016-02-29 | Pfizer Inc. | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni |
| WO2015049616A1 (en) | 2013-10-04 | 2015-04-09 | Pfizer Inc. | Novel bicyclic pyridinones as gamma-secretase modulators |
| BR112016022519A8 (pt) | 2014-04-01 | 2018-03-06 | Pfizer | cromeno e 1,1a,2,7b-tetra-hidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gama-secretase |
| JP6111002B1 (ja) | 2014-04-10 | 2017-04-05 | ファイザー・インク | ２−アミノ−６−メチル−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル−１，３−チアゾール−４−イルアミド |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| EA031201B1 (ru) | 2014-08-06 | 2018-11-30 | Пфайзер Инк. | Соединения имидазопиридазина |
| KR102000382B1 (ko) | 2015-02-03 | 2019-07-15 | 화이자 인코포레이티드 | 신규 시클로프로파벤조푸라닐 피리도피라진디온 |
| DK3310784T3 (da) | 2015-06-17 | 2020-11-09 | Pfizer | Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere |
| WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド |
| EP3353174A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors |
| KR102148587B1 (ko) | 2016-02-23 | 2020-08-26 | 화이자 인코포레이티드 | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 |
| PL3478679T3 (pl) | 2016-07-01 | 2021-10-25 | Pfizer Inc. | Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych |
| FI3642202T3 (fi) | 2017-06-22 | 2023-03-01 | Dihydro-pyrrolo-pyridiinijohdannaisia | |
| EP3768669B1 (en) | 2018-03-23 | 2023-01-25 | Pfizer Inc. | Piperazine azaspiro derivaves |
| EP4297868A4 (en) | 2021-02-23 | 2025-01-08 | Hoth Therapeutics, Inc. | USE OF APREPITANT TO TREAT ALZHEIMER'S |
| WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
| AU2024413926A1 (en) | 2023-12-29 | 2026-07-09 | Pfizer Inc. | Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
| GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
| GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
| GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| CA2288910C (en) | 1997-04-25 | 2003-06-24 | Pfizer Inc. | Pyrazolopyrimidinones for sexual dysfunction |
| HU227841B1 (en) | 1997-11-12 | 2012-05-02 | Bayer Pharma AG | 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof |
| ES2203078T3 (es) | 1998-04-20 | 2004-04-01 | Pfizer Inc. | Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual. |
| ES2205945T3 (es) | 1998-10-23 | 2004-05-01 | Pfizer Inc. | Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de disfunciones sexuales. |
| DE19942474A1 (de) | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
| HK1049834A1 (zh) | 1999-10-11 | 2003-05-30 | 辉瑞大药厂 | 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物 |
| TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| DE10031584A1 (de) | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine |
| AU2001272690B2 (en) | 2000-07-28 | 2005-12-08 | Pfizer Inc. | Crystalline therapeutic agent |
| ATE478872T1 (de) * | 2002-03-28 | 2010-09-15 | Ustav Ex Botan Av Cr V V I I O | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung |
| KR100824193B1 (ko) | 2003-04-29 | 2008-04-21 | 화이자 인코포레이티드 | 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘 |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| GB0327323D0 (en) | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
| US7572799B2 (en) * | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| JP2007532526A (ja) | 2004-04-07 | 2007-11-15 | ファイザー・インク | ピラゾロ［４，３−ｄ］ピリミジン類 |
| EP1809632A2 (en) | 2004-10-28 | 2007-07-25 | Pharmacia & Upjohn Company LLC | Pyrazolo[4,3-d]pyrimidine derivatives useful as pde-5 inhibitors |
-
2006
- 2006-05-03 PT PT06744689T patent/PT1881985E/pt unknown
- 2006-05-03 MX MX2007013215A patent/MX2007013215A/es active IP Right Grant
- 2006-05-03 DK DK06744689.8T patent/DK1881985T3/da active
- 2006-05-03 AU AU2006245416A patent/AU2006245416B2/en not_active Ceased
- 2006-05-03 KR KR1020077026098A patent/KR100939890B1/ko not_active Expired - Fee Related
- 2006-05-03 PL PL06744689T patent/PL1881985T3/pl unknown
- 2006-05-03 EA EA200702217A patent/EA012577B1/ru not_active IP Right Cessation
- 2006-05-03 NZ NZ564187A patent/NZ564187A/en not_active IP Right Cessation
- 2006-05-03 DE DE602006019231T patent/DE602006019231D1/de not_active Expired - Lifetime
- 2006-05-03 WO PCT/IB2006/001233 patent/WO2006120552A2/en not_active Ceased
- 2006-05-03 EP EP06744689A patent/EP1881985B1/en not_active Expired - Lifetime
- 2006-05-03 BR BRPI0609225-0A patent/BRPI0609225A2/pt not_active IP Right Cessation
- 2006-05-03 AT AT06744689T patent/ATE493413T1/de active
- 2006-05-03 US US11/913,091 patent/US8227475B2/en not_active Expired - Fee Related
- 2006-05-03 CA CA2608018A patent/CA2608018C/en not_active Expired - Fee Related
- 2006-05-11 TW TW095116704A patent/TWI380986B/zh not_active IP Right Cessation
- 2006-05-11 JP JP2006132110A patent/JP4271695B2/ja not_active Expired - Fee Related
-
2007
- 2007-10-12 NO NO20075258A patent/NO20075258L/no not_active Application Discontinuation
- 2007-10-16 IL IL186693A patent/IL186693A/en not_active IP Right Cessation
- 2007-11-09 CR CR9505A patent/CR9505A/es unknown
- 2007-11-09 TN TNP2007000414A patent/TNSN07414A1/fr unknown
- 2007-11-12 MA MA30362A patent/MA29447B1/fr unknown
-
2009
- 2009-01-07 JP JP2009001627A patent/JP4996631B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-08 CY CY20111100142T patent/CY1111171T1/el unknown
-
2012
- 2012-04-27 US US13/457,969 patent/US8796288B2/en not_active Expired - Fee Related
- 2012-04-27 US US13/457,886 patent/US8796287B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2608018A1 (en) | Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | |
| ES2299501T3 (es) | Compuestos heterociclicos utiles como inhibidores de tirosina-quinasas. | |
| JP2014518266A5 (cg-RX-API-DMAC7.html) | ||
| IL210071A (en) | Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation | |
| NZ591712A (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| FI2134702T4 (fi) | 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen | |
| CA2776342C (en) | Agomelatine and pharmaceutical compositions thereof | |
| JP2009537498A5 (cg-RX-API-DMAC7.html) | ||
| JP2016065042A5 (cg-RX-API-DMAC7.html) | ||
| WO2006130160A3 (en) | Furanopyridine derivatives as ack1 and lck modulators | |
| NZ719972A (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
| WO2005077950A3 (en) | Medicaments with hm74a receptor activity | |
| RU2018101363A (ru) | Кристаллическая форма свободного основания лорлатиниба | |
| JP2012512158A5 (cg-RX-API-DMAC7.html) | ||
| FI3894411T3 (fi) | 7-fenoksi-n-(3-atsabisyklo[3.2.1]oktan-8-yyli)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triatsoli-2-amiinijohdannaisia ja niihin liittyviä yhdisteitä gammasekretaasin modulaattoreina alzheimerin taudin hoitoon | |
| RU2022109286A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| JP2021515015A5 (cg-RX-API-DMAC7.html) | ||
| WO2005016867A3 (en) | Anthranilic acid derivatives and their use as activators of the hm74a receptor | |
| JP2020502224A5 (cg-RX-API-DMAC7.html) | ||
| WO2004041794A8 (en) | Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines | |
| JP2011527687A5 (cg-RX-API-DMAC7.html) | ||
| JP2009518415A5 (cg-RX-API-DMAC7.html) | ||
| JP2022549601A5 (cg-RX-API-DMAC7.html) | ||
| JP2009526776A5 (cg-RX-API-DMAC7.html) | ||
| JP2013537901A5 (cg-RX-API-DMAC7.html) |